Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02780609 · ClinicalTrials.gov registry record · Phase 1
Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02780609 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 22 participants.
The verdict
NCT02780609, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. Phase II: The primary purpose of this study phase is to assess the complete response (CR) conversion rate.
Interventions
- DRUG Melphalan
- DRUG Selinexor
- DRUG Dexamethasone
- PROCEDURE Autologous Hematopoietic Cell Transplantation (HCT)
- DRUG Fosaprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2021-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02780609
The ClinicalTrials.gov registry entry for NCT02780609 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT02780609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02780609 about?
NCT02780609 is a clinical study titled "Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma". Phase I: The primary purpose of this study phase is to determine the best dose also referred to as the maximum tolerated dose (MTD) of Selinexor when used in combination with high-dose melphalan as a conditioning regimen for hematopoietic cell transplant. Phase II: The primary purpose of this study...
What is the current status of trial NCT02780609?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2017-07-20. Estimated completion is 2021-02-23.
What interventions are being tested in trial NCT02780609?
The interventions under investigation include: Melphalan (DRUG), Selinexor (DRUG), Dexamethasone (DRUG), Autologous Hematopoietic Cell Transplantation (HCT) (PROCEDURE), Fosaprepitant (DRUG).
Who is sponsoring clinical trial NCT02780609?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.